+1 201 316 9200
+81 (0)3 6264 0600
Europe & Rest of World
+41 61 316 81 11
Pre-clinical to Commercial
In the last few years, a significant Pharmaceutical Industry presence has grown in the surrounding Tuas Biomedical Park. As a leader in global custom manufacturing, Lonza has expanded its presence in these growing Asian demographics. The Singapore project extends our worldwide custom manufacturing capacity to provide customers with further capacity to successfully develop and commercialize their important products in the global market.
Lonza’s cell culture manufacturing facility in Tuas, Biomedical Park commenced cGMP production in early 2011 with a complete range of mammalian bioreactor production systems (200L to 20,000L lot sizes) for both clinical and commercial operation. In addition, process development services were also launched in 2011.
Our Tuas, Singapore site is a mammalian cell culture manufacturing facility for the contract development and production of biopharmaceutical products, including monoclonal antibodies (mAbs), cellular therapeutics and other recombinant proteins. Lonza’s Tuas multi-product facility is located in a largely industrial area in western Singapore.
Development and Manufacturing Capabilities:
Lonza has continued its commitment to emerging markets by expanding its global footprint for Cell Therapy production. In early 2012, the completion of a second building on the Singapore site will introduce purpose-built laboratories for a full range of process development and analytical services to expand our process development services capabilities, plus cGMP manufacturing suites for cell based therapeutic products.
The Current Expansion Capacity Plans Include: